Gesynta is pleased to announce that XGen Venture, a distinguished Milan-based venture firm specialized in the life sciences sector, has joined its investor syndicate. This latest investment provides a significant capital injection, successfully expanding the company’s Series B financing round to a total of SEK 390 million.

We extend a warm welcome to XGen Venture and particularly to Daniele Scarinci, XGen Co-Founder and Managing Partner, who has accepted a position on the Gesynta company board.

The capital provided by XGen Venture is critical to our current momentum, enabling us to accelerate preparations for the Phase 3 program of our drug candidate, vipoglanstat. We have successfully initiated the Phase 2 study for this compound, which is aimed at revolutionizing the treatment landscape for endometriosis—a debilitating disease that affects an estimated 190 million women globally.